Long Term Quality of Life in Melanoma Patients in Netherlands
NCT03450876 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 89
Last updated 2020-09-11
Summary
Study of late physical, psychological and social effects in patients treated with ipilimumab for advanced (stage IV or unresectable stage III) melanoma.
Conditions
Interventions
- OTHER
-
Non-Interventional
Non-Interventional
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2016-12-15
- Primary Completion
- 2020-06-17
- Completion
- 2020-06-17
Countries
- Netherlands
Study Locations
More Related Trials
-
A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.
NCT02068196 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma
NCT03696069 ·Status: COMPLETED
-
Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
NCT01927419 ·Status: COMPLETED ·Phase: PHASE2
-
Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy
NCT03438279 ·Status: COMPLETED
-
Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma
NCT00803374 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
NCT01511913 ·Status: COMPLETED
-
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
NCT01844505 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
NCT01783938 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma
NCT01703507 ·Status: COMPLETED ·Phase: PHASE1
-
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
NCT03873818 ·Status: COMPLETED ·Phase: PHASE2
-
Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma
NCT02263508 ·Status: TERMINATED ·Phase: PHASE3
-
Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced Melanoma
NCT03504696 ·Status: COMPLETED
-
PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma
NCT01621490 ·Status: COMPLETED ·Phase: PHASE1
-
Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy
NCT02990611 ·Status: COMPLETED
-
Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma
NCT00920907 ·Status: COMPLETED ·Phase: PHASE1
-
A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)
NCT02156804 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab
NCT01515189 ·Status: COMPLETED ·Phase: PHASE3
-
An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma
NCT03068455 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma
NCT01681212 ·Status: COMPLETED ·Phase: PHASE2
-
Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity
NCT01323517 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
NCT02714218 ·Status: COMPLETED ·Phase: PHASE3
-
Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma
NCT01676649 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab
NCT02600169 ·Status: COMPLETED
-
A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma
NCT02905266 ·Status: COMPLETED ·Phase: PHASE3
-
Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma
NCT01740297 ·Status: COMPLETED ·Phase: PHASE1/PHASE2